. 2023 Jun 19;28(9):804–811. doi: 10.1093/oncolo/oyad172

Table 1.

Patient treatment patterns, by race.

Characteristic	White (n = 726)	Black (n = 198)	P-value
Patients with durvalumab treatment initiation delay^a, n (%)	275 (38)	89 (45)	.07
Patients with durvalumab treatment interruptions^b, n (%)	130 (18)	49 (25)	.03
Durvalumab treatment discontinuations, n (%)	437 (60)	106 (54)	.09

^aDurvalumab treatment delay was defined as more than 42 days from end of CRT to initiation of durvalumab.

^bDurvalumab treatment interruptions were defined as more than 28 days between durvalumab infusions.

Bold italic value indicates statistical significance.